Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-Muscle Invasive Bladder Cancer

Cancer Invest. 2023 Nov 24:1-10. doi: 10.1080/07357907.2023.2288640. Online ahead of print.ABSTRACTThe aim of the study was to demonstrate the most common genetic alterations and evaluate possible targets involving phosphatidylinositol-3-OH kinase (PIK3)/AKT/mammalian target of rapamycin (mTOR) signaling and DNA damage repair (DDR) pathways for personalized treatment in patients with non-muscle invasive bladder cancer (NMIBC). Alterations of these pathways were observed in 89.5% and 100% of patients, respectively. Among them, BARD1 was more frequently altered in low/intermediate-risk cases, but PARP4 was more frequently affected in intermediate/high-risk patients. The possible target feasibility of BARD1 and PARP4 alterations should be evaluated for personalized treatment using PARP-inhibitors in NMIBC. It is important to detect high tumor mutation burden (TMB) in patients in terms of immunotherapy.PMID:37997757 | DOI:10.1080/07357907.2023.2288640

Source: Cancer Investigation - November 24, 2023 Category: Cancer & Oncology Authors: Serdar Celik Tekincan Aktas Ozde Gokbayrak Aylin Erol Kutsal Yorukoglu Batuhan Yilmaz Hilmi Sari Zekiye Altun Mehmet Ugur Mungan Ilhan Celebi Guven Aslan Safiye Aktas Source Type: research